Brian R. Stanton

Stanton Consulting Services

Brian R. Stanton, Ph.D., works on IP, trade, and associated technology innovation policy matters. A principal in Stanton Consulting Services, Brian was previously the Director of the Division of Policy at the National Institutes of Health’s (NIH’s) Office of Technology Transfer and was responsible for IP and technology transfer policy for the U.S. Public Health Service (the NIH, the Food and Drug Administration, and the Centers for Disease Control and Prevention) until 2007. His previous appointment as an Examiner and Practice Specialist at the USPTO included efforts in establishing IP standards for bioinformatics, transgenic animals, and genomics.

He has published numerous papers addressing trade and IP policy matters. His global experience includes collaborations with the European and Japan Patent Offices, the World Trade Organization, the World Health Organization, and the Organisation for Economic Co-Operation and Development. Brian received his Ph.D. for his work in molecular oncology performed at the U.S. National Cancer Institute’s Frederick Cancer Research and Development Facility.

As a post-doctoral fellow, he utilized embryonic stem cell technology to generate animal model systems of development. Brian served on the AIPLA Special Task Force on AIA Rulemaking, a 25-member committee of experts that provided detailed comments to the USPTO on the AIA Rules pre- and post-publication; and continues to be involved in IP legislation and harmonization efforts.

He is co-author of the AIPLA/Bloomberg Law treatises Patents After the AIA: Evolving Law & Practice and Prior Art After the AIA: A Practical Guide.